Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Kadence Edelblut

Physician Assistant, Medical Norton Shores, MI Physician Assistant

NPI 1306486881 CMS profile 11205446

131 W Seaway Dr, Norton Shores, MI 49444

Open in the dashboard

General payments

$7,886

538 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kadence Edelblut of Norton Shores, MI is reported in the CMS Open Payments database as having received $7,886 across 538 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2,257 149
2022 General $3,295 236
2021 General $2,334 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kadence Edelblut
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kadence Edelblut were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kadence Edelblut Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,334 $156 $41–$563 $132
2022 $3,295 $185 $55–$649 $149
2023 $2,257 $199 $58–$717 $160
2024 $0 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $1,657 128 payments
  2. ITI, Inc. $604 34 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $435 31 payments
  4. AstraZeneca Pharmaceuticals LP $402 18 payments
  5. Amgen Inc. $363 28 payments
  6. Novo Nordisk Inc $322 23 payments
  7. Lilly USA, LLC $302 24 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $296 22 payments
  9. Otsuka America Pharmaceutical, Inc. $291 20 payments
  10. Teva Pharmaceuticals USA, Inc. $286 20 payments
  11. Other $2,928 190 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $7,886 538 payments
Products named General payments · program years 2021–2023
  1. CAPLYTA $604 34 payments
  2. LINZESS $514 31 payments
  3. VRAYLAR $499 49 payments
  4. CREON $419 26 payments
  5. NURTEC ODT $388 19 payments
  6. UBRELVY $322 30 payments
  7. STIOLTO RESPIMAT $318 24 payments
  8. BREZTRI $289 11 payments
  9. QELBREE $274 32 payments
  10. Ozempic $263 19 payments
  11. Other $7,048 446 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

2,866

Median for Physician Assistant: 241

Drug cost

$174,340

Median for Physician Assistant: $4,110

Branded share of claims

18.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 74 $42,310
Ozempic Semaglutide Brand 15 $16,062
Xarelto Rivaroxaban Brand 19 $10,769
Atorvastatin Calcium Generic 226 $9,571
Entresto Sacubitril/Valsartan Brand 12 $8,673
Myrbetriq Mirabegron Brand 15 $6,977
Omeprazole Generic 124 $5,171
Donepezil Hcl Generic 79 $4,112
Pregabalin Generic 43 $3,755
Quetiapine Fumarate Generic 39 $3,122

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Records

538 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record